Transendocardial Injection of Expanded Autologous CD34+ Cells After Myocardial Infarction: Results of the EXCELLENT Trial

Jerome Roncalli, MD, PHD^a, François Roubille, MD, PHD ^b, Yves Cottin, MD, PHD ^c, Lionel Leroux, MD, PHD^d, Anthony Mathur, MD, PHD^e, John Irving, MD^f, Sohail Q. Khan, MB CHB, MD ^g, Nicolas Meneveau, MD, PHD ^h, Didier Bresson, MD ⁱ, Thomas Hovasse, MD ^j, Giulio Pompilio, MD, PHD ^k,l, Anthony Matta, MD, PHD ^a, Philippe Henon, MD ^m, Guillaume Trebuchet, PHD ^m, Matthieu de Kalbermatten, MS, MBA ^m, Ibon Garitaonandia, PHD, MBA ^m, Eric Saloux, MD, PHD ⁿ, Alain Manrique, MD, PHD ^o, Nicolas Meyer, MD, PHD ^p, Pierre-Yves Marie, MD, PHD^q, Deepak L. Bhatt, MD, MPH, MBA^r, Scott D. Solomon, MD^s, Gilles Montalescot, MD, PHD^t, David E. Newby, MD, PHD^u, Faiez Zannad, MD, PHD^v, the EXCELLENT Trial Investigators

JACC: HEART FAILURE Volume 13, Issue 11, November 2025, 102626 | https://doi.org/10.1016/j.jchf.2025.102626